Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanobody-based IgG simultaneously inhibit the allergenic and enzymatic activity of the dominant honeybee venom allergen.

Nature communications·2026
Same author

[Insect Venom Allergy 2025 - What should ENT Specialists know?]

Laryngo- rhino- otologie·2025
Same author

Successful tolerance induction by allergen immunotherapy in a patient with bee venom anaphylaxis under treatment with a Janus kinase 1/2 inhibitor.

The journal of allergy and clinical immunology. In practice·2025
Same author

Booster Injection with Birch Pollen Extract Activates B-Cellular Memory Responses in Patients Having Completed Allergen Immunotherapy.

European journal of immunology·2025
Same author

Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus.

The British journal of dermatology·2025
Same author

[A different kind of tongue burning!]

Laryngo- rhino- otologie·2025

Related Experiment Video

Updated: Jul 3, 2026

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Selectable bicistronic vectors in skin gene therapy.

Frank Scheidemann1, Jean-Philippe Therrien, Wolfgang Pfützner

  • 1Department of Dermatology and Allergology, University of Munich, Munich, Germany.

Archives of Dermatological Research
|July 30, 2008
PubMed
Summary

Bicistronic vectors (BCV) show promise for skin gene therapy, with construct design and cell type significantly impacting gene expression. The QGIM vector, utilizing a CMV promoter, demonstrated superior efficiency in transducing keratinocytes and fibroblasts and enabling drug selection.

More Related Videos

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
06:21

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector
10:13

An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector

Published on: January 12, 2018

Related Experiment Videos

Last Updated: Jul 3, 2026

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
06:21

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector
10:13

An Efficient In Vitro Transposition Method by a Transcriptionally Regulated Sleeping Beauty System Packaged into an Integration Defective Lentiviral Vector

Published on: January 12, 2018

Area of Science:

  • Gene Therapy
  • Molecular Biology
  • Dermatology

Background:

  • Bicistronic vectors (BCV) enable co-expression of a therapeutic gene and a selectable marker, facilitating gene therapy applications.
  • The efficacy of BCVs is influenced by vector design elements, including promoter choice and gene order, as well as the target cell type.

Purpose of the Study:

  • To investigate the impact of different BCV designs on gene expression efficiency in skin cells (keratinocytes and fibroblasts).
  • To identify the optimal BCV construct for cutaneous gene therapy applications, considering both transduction efficiency and drug selection capabilities.

Main Methods:

  • Transduction of human keratinocytes (KC) and fibroblasts (FB) with three distinct BCV constructs: BGIM (LTR promoter), BMIG (LTR promoter, reversed gene order), and QGIM (CMV promoter).
  • Flow cytometry (FACS) analysis to quantify the percentage of transduced cells and measure green fluorescent protein (GFP) expression intensity.
  • Colchicine selection to assess the enrichment efficiency of drug-resistant cells.
  • Immunohistochemistry and FACS analysis of skin equivalents to evaluate BCV performance in a more complex tissue model.

Main Results:

  • The QGIM vector, driven by a CMV promoter, achieved the highest transduction rates in both KC (47.9%) and FB (56.7%).
  • While BGIM showed higher GFP intensity, QGIM and BMIG vectors enabled highly efficient enrichment (up to 97.8%) via colchicine selection, unlike BGIM.
  • Colchicine selection of QGIM-transduced skin equivalents significantly increased the proportion of GFP-expressing KC (from 51.2% to 72.3%) and enhanced GFP intensity.

Conclusions:

  • Bicistronic vectors are a viable strategy for enhancing gene expression in skin, but careful consideration of vector backbone, gene arrangement, and target cell type is crucial.
  • The QGIM vector, with its CMV promoter and specific gene order, demonstrates superior performance for cutaneous gene therapy, particularly in achieving efficient drug-mediated cell enrichment.